Furthermore, Zhang et al. recently reported the first successful control of disease with sirolimus in treating intravenous leiomyomatosis [19], and another mTOR inhibitor, everolimus, in treating a PBML patient achieved partial remission lasting 57 months [11]. The gene discussed is MTOR; the disease is leiomyomatosis.